1887
Volume 2013, Issue 2
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

Vitiligo is an acquired pigmentry disorder of the skin and mucous membranes which manifests as white macules and patches due to selective loss of melanocytes. Etiological hypotheses of vitiligo include genetic, immunological, neurohormonal, cytotoxic, biochemical, oxidative stress and newer theories of melanocytorrhagy and decreased melanocytes survival. There are several types of vitiligo which are usually diagnosed clinically and by using a Wood's lamp; also vitiligo may be associated with autoimmune diseases, audiological and ophthalmological findings or it can be a part of polyendocrinopathy syndromes. Several interventions are available for the treatment for vitiligo to stop disease progression and/or to attain repigmentation or even depigmentation. In this article, we will present an overall view of current standing of vitiligo research work especially in the etiological factors most notably the genetic components, also, types and associations and various and newer treatment modalities.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2013.10
2014-05-01
2019-10-22
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2013/2/qmj.2013.10.html?itemId=/content/journals/10.5339/qmj.2013.10&mimeType=html&fmt=ahah

References

  1. [1]. Picardo   M. . Taiieb A: Vitiligo . Heidelberg: : Springer;   2010; .
    [Google Scholar]
  2. [2]. Birlea   SA., , Spritz   RA. . Norris DA: Vitiligo. . In: Wolff   K. , ed. Fitzpatric's Dermatology in General Medicine . , 8th ed..   New York: : McGraw-Hill;   in press; .
    [Google Scholar]
  3. [3]. Alkhateeb   A., , Fain   PR., , Thody   A., , Bennett   DC., , Spritz   RA. . Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their relatives. . Pigment Cell Res . 2003; ;16: : 208– 214 .
    [Google Scholar]
  4. [4]. Kyriakis   KP., , Palamaras   I., , Tsele   E., , Michailides   C., , Terzoudi   S. . Case detection rates of vitiligo by gender and age. . Int J Dermatol . 2009; ;48: : 328– 329 .
    [Google Scholar]
  5. [5]. Alikhan   A., , Felsten   LM., , Daly   M., , Petronic-Rosic   V. . Vitiligo: A comprehensive overview Part 1. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work up. . J Am Acad Dermatol . 2011; ;65: : 473– 491 .
    [Google Scholar]
  6. [6]. Nordlund   JJ., , Ortonne   J-P. . Vitiligo Vulgaris. . In: Nordlund   JJ., Boissy   RE., Hearing   VJ., King   RA., Ortonne   J-P. , eds. The Pigmentry System . New York: : Oxford University Press;   1993; ; : 513– 551 .
    [Google Scholar]
  7. [7]. Hann   S-K., , Nordlund   J. . Vitiligo . Oxford: : Blackwell Science;   2000; .
    [Google Scholar]
  8. [8]. Spritz   RA. . The genetics of generalized vitiligo and associated autoimmune diseases. . J Dermatol Science . 2006; ;41: : 3– 10 .
    [Google Scholar]
  9. [9]. Linthorst Homan   MW., , Sprangers   MA., , de Korte   J., , Bos   JD., , van der Veen   JP. . Characteristics of patients with universal vitiligo and health related quality of life. . Arch Dermatol . 2008; ;144: : 1062– 1064 .
    [Google Scholar]
  10. [10]. Barona   MI., , Arrrunategui   A., , Falabella   R., , Alzate   A. . An epidemiologic case-control study in a population with vitiligo. . J Am Acad Dermatol . 1995; ;33: : 621– 625 .
    [Google Scholar]
  11. [11]. Halder   RM., , Taliaferro   SJ. . Vitiligo. . In: Wolff   K.., Goldsmith   L., Katz   S., Gilchrest   B., Paller   A., Lefell   D. , eds. Fitzpatrick's dermatology in general medicine . New York: : McGraw-Hill;   2008; :p. 72 .
    [Google Scholar]
  12. [12]. Spritz   RA. . Genetics. . In: Picardo   M., Taieb   A. , eds. Vitiligo . Heidelberg: : Springer-Verlag;   2010; :p. 155 .
    [Google Scholar]
  13. [13]. Alkhateeb   A., , Fain   PR., , Thody   A., , Bennett   DC., , Spritz   RA. . Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. . Pigment Cell Res . 2003; ;16: : 208– 214 .
    [Google Scholar]
  14. [14]. Hann   SK., , Lee   HJ. . Segmental vitiligo: clinical findings in 208 patients. . J Am Acad Dermatol . 1996; ;35: : 671– 674 .
    [Google Scholar]
  15. [15]. Gauthier   Y., , Cario Andre   M., , Taieb   A. . A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?.   Pigment Cell Res . 2003; ;16: : 322– 332 .
    [Google Scholar]
  16. [16]. Le Poole   IC., , Das   PK., , van den Wijngaard   RM., , Bos   JD., , Westerhof   W. . Review of the etiopathomechanism of vitiligo: a convergence theory. . Exp Dermatol . 1993; ;2: : 145– 153 .
    [Google Scholar]
  17. [17]. Grimes   PE., , Morris   R., , Avaniss-Aghajani   E., , Soriano   T., , Meraz   A. . Topical tacrolimus therapy in vitiligo: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. . J Am Acad Dermatol . 2004; ;51: : 52– 61 .
    [Google Scholar]
  18. [18]. Rästep   R., , Kingo   K., , Karelson   M., , Reimann   E., , Raud   K., , Silm   H., , Vasar   E., , Kõks   S. . Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. . Br J Dermatol . 2008; ;159: : 1275– 1281 .
    [Google Scholar]
  19. [19]. Reimann   E., , Kingo   K., , Karelson   M., , Reemann   P., , Loite   U., , Sulakatko   H., , Keermann   M., , Raud   K., , Abram   K., , Vasar   E., , Silm   H., , Kõks   S. . The mRNA expression profile of cytokines connected to the regulation of melanocyte functioning in vitiligo skin biopsy samples and peripheral blood mononuclear cells. . Human Immunol . 2012; ;73: : 393– 398 .
    [Google Scholar]
  20. [20]. Stimuli   M., , Ancans   J., , Thody   AJ. . Melanocyte function and its control by melanocortin peptides. . J Histochem Cytochem . 2002; ;50: : 125– 133 .
    [Google Scholar]
  21. [21]. Slominski   A., , Wortsman   J., , Mazurkeiwicz   JE., , Matsuoka   L., , Dietrich   J., , Lawrence   K., , Gorbani   A., , Paus   R. . Detection of proopiomelanocortin-derived antigens in normal and pathologic human skin. . J Lab Clin Med . 1993; ;122: : 658– 666 .
    [Google Scholar]
  22. [22]. Thody   AJ., , Ridley   K., , Penny   RJ., , Chalmers   R., , Fisher   C., , Shuster   S. . MSH peptides are present in mammalian skin. . Peptides . 1983; ;4: : 813– 816 .
    [Google Scholar]
  23. [23]. Pichler   R., , Sfetsos   K., , Badics   B., , Gutenbrunner   S., , Aubock   J. . Vitiligo patients present lower plasma levels of alpha melanotropin immunoreactivities. . Neuropeptides . 2006; ;40: : 177– 183 .
    [Google Scholar]
  24. [24]. Graham   A., , Westerhof   W., , Thody   AJ. . The expression of alpha-MSH by melanocytes is reduced in vitiligo. . Ann NY Acad Sci . 1999; ;885: : 470– 473 .
    [Google Scholar]
  25. [25]. Kingo   K., , Aunin   E., , Karelson   M., , Philips   MA., , Rästep   R., , Silm   H., , Vasar   E., , Soomets   U., , Kõks   S. . Gene expression analysis of melanocortin system in vitiligo. . J Dermatol Sci . 2007; ;48: : 113– 122 .
    [Google Scholar]
  26. [26]. Birlea   SA., , Gowan   K., , Fain   PR., , Spritz   RA. . Genome wide-association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8. . J Investig Dermatol . 2010; ;130: : 798– 803 .
    [Google Scholar]
  27. [27]. Jin   Y., , Birlea   SA., , Fain   PR., , Gowan   K., , Riccardi   SL., , Holland   PJ., , Mailloux   CM., , Sufit   AJD., , Hutton   SM., , Amadi-Myers   A., , Bennett   DC., , Wallace   MR., , McCormack   WT., , Kemp   EH., , Gawkrodger   DJ., , Weetman   AP., , Picardo   M., , Leone   G., , Taieb   A., , Jouary   T., , Ezzedine   K., , van Geel   N., , Lambert   J., , Overbeck   A., , Spritz   RA. . Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. . N Engl J Med . 2010; ;362: : 1686– 1697 .
    [Google Scholar]
  28. [28]. Jin   Y., , Birlea   SA., , Fain   PR., , Mailloux   CM., , Riccardi   SL., , Gowan   K., , Holland   PJ., , Bennett   DC., , Wallace   MR., , McCormack   WT., , Kemp   EH., , Gawkrodger   DJ., , Weetman   AP., , Picardo   M., , Leone   G., , Taïeb   A., , Jouary   T., , Ezzedine   K., , van Geel   N., , Lambert   J., , Overbeck   A., , Spritz   RA. . Common variants of FOXP1 are associated with generalized vitiligo. . Nat Genet . 2010; ;42: : 576– 578 .
    [Google Scholar]
  29. [29]. Quan   C., , Ren   YQ., , Xiang   LH., , Sun   LD., , Xu   AE., , Gao   XH., , Chen   HD., , Pu   XM., , Wu   RN., , Liang   CZ., , Li   JB., , Gao   TW., , Zhang   JZ., , Wang   XL., , Wang   J., , Yang   RY., , Liang   L., , Yu   JB., , Zuo   XB., , Zhang   SQ., , Zhang   SM., , Chen   G., , Zheng   XD., , Li   P., , Zhu   J., , Li   YW., , Wei   XD., , Hong   WS., , Ye   Y., , Zhang   Y., , Wu   WS., , Cheng   H., , Dong   PL., , Hu   DY., , Li   Y., , Li   M., , Zhang   X., , Tang   HY., , Tang   XF., , Xu   SX., , He   SM., , Lv   YM., , Shen   M., , Jiang   HQ., , Wang   Y., , Li   K., , Kang   XJ., , Liu   YQ., , Sun   L., , Liu   ZF., , Xie   SQ., , Zhu   CY., , Xu   Q., , Gao   JP., , Hu   WL., , Ni   C., , Pan   TM., , Li   Y., , Yao   S., , He   CF., , Liu   YS., , Yu   ZY., , Yin   XY., , Zhang   FY., , Yang   S., , Zhou   Y., , Zhang   XJ. . Genome wide-association study for vitiligo identifies susceptibility loci at 6q27 and MHC. . Nat Genet . 2010; ;42: : 614– 618 .
    [Google Scholar]
  30. [30]. Liu   J., , Tang   H., , Zuo   X., , Liang   B., , Wang   P., , Sun   L., , Yang   S., , Zhang   X. . A single nucleotide polymorphism rs9468925 of MHC region is associated with clinical features of generalized vitiligo in Chinese Han population. . J Eur Acad Dermatol Venereol . 2012; ;26: 9 : 1137– 1141 .
    [Google Scholar]
  31. [31]. Spritz   LA. . The genetics of generalized vitiligo: autoimmune pathways and inverse relation with malignant melanoma. . Genome Med . 2010; ;2: : 78– 82 .
    [Google Scholar]
  32. [32]. Birlea   SA., , Jin   Y., , Bennett   DC., , Herbstman   DM., , Wallace   MR., , McCormack   WT., , Kemp   EH., , Gawkrodger   DJ., , Weetman   AP., , Picardo   M., , Leone   G., , Taïeb   A., , Jouary   T., , Ezzedine   K., , van Geel   N., , Lambert   J., , Overbeck   A., , Fain   PR., , Spritz   RA. . Comprehensive association analysis of candidate genes for generalized vitiligo supports XBP1, FOXP3, AND TSLP. . J Invest Dermatol . 2011; ;131: : 371– 381 .
    [Google Scholar]
  33. [33]. Alkhateeb   A., , Qarqaz   F. . Genetic association of NALP1 with generalized vitiligo in Jordanian Arabs. . Arch Dermatol Res . 2010; ;302: 8 : 631– 634 .
    [Google Scholar]
  34. [34]. Jin   Y., , Riccardi   SL., , Gowan   K., , Fain   PR., , Spritz   RA. . Fine-mapping of vitiligo susceptibility loci on chromosome 7 and 9 and interactions with NLRP1 (NALP1). . J Invest Dermatol . 2010; ;130: : 774– 783 .
    [Google Scholar]
  35. [35]. Ongenae   K., , Van Geel   N., , Naeyraert   JM. . Evidence of an autoimmune pathogenesis of vitiligo. . Pigment Cell Res . 2003; ;16: : 90– 100 .
    [Google Scholar]
  36. [36]. Sandoval-Cruz   M., , García-Carrasco   M., , Sánchez-Porras   R., , Mendoza-Pinto   C., , Jiménez-Hernández   M., , Munguía-Realpozo   P., , Ruiz-Argüelles   A. . Immunopathogenesis of vitiligo. . Autoimmun Rev . 2011; ;10: : 762– 765 .
    [Google Scholar]
  37. [37]. Passeron   T., , Ortonne   JP. . Pathophysiology and genetics of vitiligo. . J Autoimmun . 2005; ;25: : 63– 68 .
    [Google Scholar]
  38. [38]. Abu Tahir   M., , Pramod   K., , Ansari   SH., , Ali   J. . Current remedies for vitiligo. . Autoimmun Rev . 2010; ;9: 7 : 516– 520 .
    [Google Scholar]
  39. [39]. Ali   R., , Ahsan   MS., , Azad   MA., , Ullah   MA., , Bari   W., , Islam   SN., , Yeasmin   S., , Hasnat   A. . Immunoglobulin levels in vitiligo patients. . Pak J Pharm Sci . 2010; ;23: : 96– 102 .
    [Google Scholar]
  40. [40]. Li   YL., , Yu   CL., , Yu   HS. . IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-DR and intercellular adhesion molecule 1expression and increased IL-8 release by melanocytes. . J Invest Dermatol . 2000; ;115: : 969– 973 .
    [Google Scholar]
  41. [41]. Kemp   EH., , Gavalas   NG., , Gawkrodger   DJ., , Weetman   AP. . Autoantibody responses to melanocytes in the depigmenting skin disease vitiligo. . Autoimmun Rev . 2007; ;3: : 138– 142 .
    [Google Scholar]
  42. [42]. Michelsen   D. . The Double Strike hypothesis of the vitiligo pathomechanism: New approaches to vitiligo and melanoma. . Medical Hypotheses . 2010; ;74: : 67– 70 .
    [Google Scholar]
  43. [43]. Klarquist   J., , Denmen   CJ., , Hernandez   C., , Wainwright   DA., , Strickland   FM., , Overbeck   A., , Mehrotra   S., , Nishimura   MI., , Le Poole   IC. . Reduced skin homing by functional Treg in vitiligo. . Pigment Cell Melanoma Res . 2010; ;23: : 276– 286 .
    [Google Scholar]
  44. [44]. van Geel   NAC., , Mollet   IG., , De Schepper   S., , Tjin   EP., , Vermaelen   K., , Clark   RA., , Kupper   TS., , Luiten   RM., , Lambert   J. . First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. . Pigment Cell Melanoma Res . 2010; ;23: : 375– 384 .
    [Google Scholar]
  45. [45]. Lili   Y., , Yi   W., , Ji   Y., , Yue   S., , Weimin   S., , Ming   L. . Global Activation of CD8+ Cytotoxic T Lymphocytes Correlates with an Impairment in Regulatory T Cells in Patients with Generalized Vitiligo. . PloS ONE . 2012; ;7: : 1– 10 .
    [Google Scholar]
  46. [46]. Zhou   L., , Li   K., , Shi   YL., , Hamzavi   I., , Gao   TW., , Henderson   M., , Huggins   RH., , Agbai   O., , Mahmoud   B., , Mi   X., , Lim   HW., , Mi   QS. . Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells. . Pigment Cell Melanoma Res . 2012; ;25: : 602– 611 .
    [Google Scholar]
  47. [47]. Hann   SK., , Chun   W. . Autocytotoxic hypothesis for the destruction of melanocytes as the cause of vitiligo. . In: Hann   SK., Nordlund   J. , eds. Vitiligo . Oxford: : Blackwell Science Ltd;   2000; .
    [Google Scholar]
  48. [48]. Schallreuter   KU., , Wood   JM., , Berger   J. . Low catalase level in the epidermis in patients with vitiligo. . J Invest Dermatol . 1991; ;97: : 1081– 1085 .
    [Google Scholar]
  49. [49]. Schallreuter   KU., , Moore   J., , Wood   JM., , Beazley   WD., , Gaze   DC., , Tobin   DJ., , Marshall   HS., , Panske   A., , Panzig   E., , Hibberts   NA. . In vivo and in vitro evidence for hydrogen peroxide (H2O2) accumulation IN THE EPIDERMIS of patients with vitiligo and its successful removal by UVB-activated pseudocatalase. . J Inest Dermatol Sym Proc . 1999; ;4: : 91– 96 .
    [Google Scholar]
  50. [50]. Casp   CB., , She   JX., , McCormack   WT. . Genetic association of the catalase gene (CAT) with vitiligo susceptibility. . Pigment Cell Res . 2002; ;15: : 62– 66 .
    [Google Scholar]
  51. [51]. Glassman   SJ. . Vitiligo, reactive oxygen species and T-cells. . Clinical Science . 2011; ;120: : 99– 120 .
    [Google Scholar]
  52. [52]. Schallreuter   KU., , Wood   JM., , Pittelkow   MR., , Gutlich   M., , Lemke   KR., , Rodl   W., , Swanson   NN., , Hitzemann   K., , Ziegler   I. . Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. . Science . 1994; ;263: : 1444– 1446 .
    [Google Scholar]
  53. [53]. Schallreuter   KU., , Buttner   G., , Pittelkow   MR., , Wood   JM., , Swanson   NN., , Korner   C. . Cytotoxicity of 6-biopterin to human melanocytes. . Biochem Biophys Res Commun . 1994; ;204: : 43– 48 .
    [Google Scholar]
  54. [54]. Le Poole   IC., , van den Wijngaard   RM., , Westerhof   W., , Das   PK. . Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. . Br J Dermatol . 1997; ;137: : 171– 178 .
    [Google Scholar]
  55. [55]. Kitamura   R., , Tsukamoto   K., , Harada   K., , Shimizu   A., , Shimada   S., , Kobayashi   T., , Imokawa   G. . Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: rple od SCF/KIT interactions and the downstream effector MITF-M. . J Pathol . 2004; ;202: : 465– 475 .
    [Google Scholar]
  56. [56]. Lee   AY., , Kim   NH., , Choi   WL., , Youm   YH. . Less keratinocyte-derived factors related to more keratinocyte apoptosis in depigmented than normally pigmented suction-blistered epidermis may lead to may cause passive melanocyte death in vitiligo. . J Invest Dermatol . 2005; ;123: : 976– 983 .
    [Google Scholar]
  57. [57]. Ezzedine   K., , Lim   HW., , Suzuki   T., , Katayama   I., , Hamzavi   I., , Lan   CC., , Goh   BK., , Anbar   T., , Silva de Castro   C., , Lee   AY., , Parsad   D., , van Geel   N., , Le Poole   IC., , Oiso   N., , Benzekri   L., , Spritz   R., , Gauthier   Y., , Hann   SK., , Picardo   M., , Taieb   A. . Vitiligo Global Issue Consensus Conference Panelists. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. . Pigment Cell Melanoma Res . 2012; ;25: : E1– E13 .
    [Google Scholar]
  58. [58]. Mazereeuw-Hautier   J., , Bezio   S., , Mahe   E., , Bodemer   C., , Eschard   C., , Viseux   V., , Labreze   C., , Plantin   P., , Barbarot   S., , Vabres   P., , Martin   L., , Paul   C., , Lacour   JP., , Groupe de Recherche Clinique en Dermatologie Pédiatrique (GRCDP). . Segmental and nonsegmental childhood vitiligo have distinct clinical characteristics: A prospective observational study. . J Am Acad Dermatol . 2010; ;62: : 945– 949 .
    [Google Scholar]
  59. [59]. van Geel   N., , De Lille   S., , Vandenhaute   S., , Gauthier   Y., , Mollet   I., , Brochez   L., , Lambert   J. . Different phenotypes of segmental vitiligo based on a clinical observational study. . J Eur Acad Dermatol Venereol . 2011; ;25: : 673– 678 .
    [Google Scholar]
  60. [60]. Ingordo   V., , Gentile   C., , Lannazzone   SS., , Cusano   F., , Naldi   L. . Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males. . Eur Acad Dermatol Venereol . 2011; ;1: : 105– 109 .
    [Google Scholar]
  61. [61]. Akay   BN., , Bozkir   M., , Anadolu   Y., , Gullu   S. . Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. . J Eur Acad Dermatol Venereol . 2010; ;24: : 1144– 1150 .
    [Google Scholar]
  62. [62]. Aslan   S., , Serarslan   G., , Teksoz   E., , Dagli   S. . Audiological and transient evoked otoacoustic emission findings in patients with vitiligo. . Otolaryngol Head Neck Surg . 2010; ;142: : 409– 414 .
    [Google Scholar]
  63. [63]. Bolognia   JL., , Orlow   SJ. . Melanocyte biology. . In: Bolognia   JL., Jorizzo   J., Rapini   PR. , eds. Dermatology . , 2nd ed..   Spain: : Mosby Elsevier;   2008; ; : 901– 911 .
    [Google Scholar]
  64. [64]. Schrott   A., , Spoendlin   H. . Pigment anomaly-associated inner ear deafness. . Acta Otolaryngol . 1987; ;7: : 17– 32 .
    [Google Scholar]
  65. [65]. Steel   KP., , Barkawy   C. . Another role for melanocytes: their importance for normal stria vascularis development in the mammalian inner ear. . Development . 1989; ;107: : 453– 463 .
    [Google Scholar]
  66. [66]. Shields   CL., , Ramasubramanian   A., , Kunz   WB., , Aggarwal   E., , Shields   JA. . Choroidal vitiligo masquerading as large choroidal nevus: a report of four cases. . Ophthalmology . 2010; ;117: 1 : 109– 113 .
    [Google Scholar]
  67. [67]. Nordlund   JJ., , Taylor   NT., , Albert   DM., , Wagoner   MD., , Lerner   AB. . The prevalence of vitiligo and poliosis in patients with uveitis. . J Am Acad Dermatol . 1981; ;4: : 528– 536 .
    [Google Scholar]
  68. [68]. da Silva   FT., , Damico   FM., , Marin   ML., , Goldberg   AC., , Hirata   CE., , Takiuti   PH., , Olivalves   E., , Yamamoto   JH. . Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: consideration on the different disease categories. . Am J Ophthalmol . 2009; ;147: : 339– 345 .
    [Google Scholar]
  69. [69]. Hamadah   I., , Binamer   Y., , Sanai   FM., , Abdo   AA., , Alajlan   A. . Interferon induced vitiligo in hepatitis C patients: a case series. . Int J Dermatol . 2010; ;49: : 829– 833 .
    [Google Scholar]
  70. [70]. Tinio   P., , Hadi   A., , Al-Ghaithi   K., , Al-Qari   H., , Rudikoff   D. . Segmental vitiligo and hair curling after interferon alpha and ribavirin treatment for hepatitis C. . Skinmed . 2006; ;5: : 50– 51 .
    [Google Scholar]
  71. [71]. Fattovich   C., , Giustina   G., , Favarato   S., , Ruol   A. . A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alpha interferon. . J Hepatol . 1996; ;24: : 38– 47 .
    [Google Scholar]
  72. [72]. Brenstien   D., , Reddy   KR., , Jeffers   L., , Scheiff   E. . Canities and vitiligo complicating interferon therapy for hepatitis C. . Am J Gastenterol . 1995; ;90: : 1176– 1177 .
    [Google Scholar]
  73. [73]. Tomasiewicz   K., , Modrzewska   R., , Semczuk   G. . Vitiligo associated with pegylated interferon and ribavirin treatment of patients with chronic hepatitis C: a case report. . Adv Ther . 2006; ;23: : 139– 142 .
    [Google Scholar]
  74. [74]. Primo   J., , Merino   C., , Gomez Belda   AB. . Vitiligo and alopecia in patients with chronic hepatitis C treated with alpha interferon associated or not with ribavirin. . Gasterol Hepatol . 2000; ;23: : 362– 363 .
    [Google Scholar]
  75. [75]. Simsek   H., , Savas   C., , Akkiz   H., , Telatar   H. . Interferon induced vitiligo in a patient with chronic hepatitis C infection. . Dermatology . 1996; ;193: : 65– 66 .
    [Google Scholar]
  76. [76]. Anbar   TS., , Abdel-Rahman   AT., , Ahmed   HM. . Vitiligo occurring at site of interferon α 2b injection in a patient with chronic viral hepatitis C: a case report. . Clin Exp Dermatol . 2008; ;33: 4 : 503 .
    [Google Scholar]
  77. [77]. Ayra   V., , Bansal   M., , Girard   L., , Arya   S., , Valluri   A. . Vitiligo at injection site of PEG-IFN α 2a in two patients with chronic hepatitis C: case report and literature review. . Case Rep Dermatol . 2010; ;2: : 156– 164 .
    [Google Scholar]
  78. [78]. Silverberg   JI., , Silverberg   AI., , Malka   E., , Silverberg   NB. . A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. . J Am Acad Dermatol . 2010; ;62: 6 : 937– 941 .
    [Google Scholar]
  79. [79]. Silverberg   NB. . Update on childhood vitiligo. . Curr Opion Pediatr . 2010; ;22: 4 : 445– 452 .
    [Google Scholar]
  80. [80]. Taieb   A., , Alomar   A., , Böhm   M., , Dell'anna   ML., , De Pase   A., , Eleftheriadou   V., , Ezzedine   K., , Gauthier   Y., , Gawkrodger   DJ., , Jouary   T., , Leone   G., , Moretti   S., , Nieuweboer-Krobotova   L., , Olsson   MJ., , Parsad   D., , Passeron   T., , Tanew   A., , van der Veen   W., , van Geel   N., , Whitton   M., , Wolkerstorfer   A., , Picardo   M., , Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). . Guidelines for the management of vitiligo: the European Dermatology Forum consensus. . Br J Dermatol . 2012; ;168: : 5– 19 .
    [Google Scholar]
  81. [81]. Gawkrodger   DJ., , Ormerod   AL., , Shaw   L., , Mauri-Sole   I., , Whitton   ME., , Watts   MJ., , Anstey   AV., , Ingham   J., , Young   K., , Therapy Guidelines and Audit Subcommittee, British Association of Dermatologists; Clinical Standards Department, Royal College of Physicians of London; Cochrane Skin Group; Vitiligo Society. . Guideline for the diagnosis and management of vitiligo. . Br J Dermatol . 2008; ;159: : 1051– 1076 .
    [Google Scholar]
  82. [82]. Njoo   MD., , Spuls   PI., , Bos   JD., , Westerhof   W., , Bossuyt   PM. . Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. . Arch Dermatol . 1998; ;134: : 1532– 1540 .
    [Google Scholar]
  83. [83]. Westerhof   W., , Nieuwboer-Krobotova   L., , Mulder   PGH., , Glazenberg   EJ. . Left-right comparison study of the combination of fluticasone propionate and UV-A vs either fluticasone or UV-A alone for the long-term treatment of vitiligo. . Arch Dermatol . 1999; ;135: : 1061– 1066 .
    [Google Scholar]
  84. [84]. Kumari   J. . Vitiligo treated with topical clobetasol propionate. . Arch Dermatol . 1984; ;120: : 631– 635 .
    [Google Scholar]
  85. [85]. Schaffer   JV., , Bolognia   JL. . The treatment of hypopigmentation in children. . Clin Dermatol . 2003; ;21: : 296– 310 .
    [Google Scholar]
  86. [86]. Cockayne   SE., , Messenger   AG., , Gawkrodger   DJ. . Vitiligo treated with topical corticosteroids: children with head and neck involvement respond well. . J Am Acad Dermatol . 2002; ;46: : 964– 965 .
    [Google Scholar]
  87. [87]. Lepe   V., , Moncada   B., , Castanedo-Cazares   JP., , Torres-Alvares   MB., , Ortis   CA., , Torres-Rubalcava   AB. . A double-blind randomized trial of 0.1% tacrolimus vs clobetasol 0.05% for the treatment of childhood vitiligo. . Arch Dermatol . 2003; ;139: : 581– 585 .
    [Google Scholar]
  88. [88]. Coskun   B., , Saral   Y., , Tugurt   D. . Topical 0.05% clobetasol propionate vs 1% pimecrolimus oint in vitiligo. . Eur J Dermatol . 2005; ;15: : 88– 91 .
    [Google Scholar]
  89. [89]. Kwinter   J., , Pelletier   J., , Kambalia   A., , Pop   E. . High potency steroid use in children with vitiligo: a retrospective study. . J Am Acad Dermatol . 2007; ;56: : 236– 241 .
    [Google Scholar]
  90. [90]. Grimes   PE., , Soriano   T., , Dytoc   MT. . Topical tacrolimus for repigmentation of vitiligo. . J Am Acad Dermatol . 2002; ;47: : 789– 791 .
    [Google Scholar]
  91. [91]. Castro   AP. . Calcineurin inhibitors in the treatment of allergic dermatitis. . J Pediatr . 2006; ;82: 5 : s166– s172 .
    [Google Scholar]
  92. [92]. Lan   CCE., , Wu   CS., , Chen   GS., , Yu   HS. . FK506 (tacrolimus) and endothelin combined treatment induce mobility of melanoblasts: new insight into follicular vitiligo repigmentation induced by topical tacrolimus in sun-exposed skin. . Br J Dermatol . 2011; ;164: : 490– 496 .
    [Google Scholar]
  93. [93]. Dawid   M., , Veensalu   M., , Grassberger   M., , Wolff   K. . Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of randomized, double-blind, vehicle-controlled study. . J Dtsh Dermatol Ges . 2006; ;4: : 942– 946 .
    [Google Scholar]
  94. [94]. Souze Leite   RM., , Craverio Leite   AA. . Two therapeutic challenges: periocular and genital vitiligo in children unsuccessfully treated with pimecrolimus cream. . Int J Dermatol . 2007; ;46: : 986– 989 .
    [Google Scholar]
  95. [95]. Ostavari   N., , Passeron   T., , Lacour   JP., , Ortonne   JP. . Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. . Arch Dermatol . 2006; ;142: : 252– 253 .
    [Google Scholar]
  96. [96]. Passeron   T., , Ostavari   N., , Zakaria   W., , Fontas   E., , Larroury   JC., , Lacour   JP., , Ortonne   JP. . Topical tacrolimus and 308-excimer laser: a synergistic combination for the treatment of vitiligo. . Arch Dermatol . 2004; ;140: : 1065– 1069 .
    [Google Scholar]
  97. [97]. Hartmann   A., , Brocker   EB., , Hamm   H. . Occlusive treatment enhances the efficacy of tacrolimus 0.1% oint in adult patients with vitiligo: results of placebo-controlled 12-months prospective study. . Acta Dermatol Venereol . 2008; ;88: : 474– 479 .
    [Google Scholar]
  98. [98]. Hartmann   A., , Brocker   EB., , Hamm   H. . repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion. . J Deutschen Dermat Ges . 2008; ;6: : 383– 385 .
    [Google Scholar]
  99. [99]. Stinco   G., , Piccirillo   F., , Forcione   M., , Valent   F., , Patrone   P. . An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. . Eur J Dermatol . 2009; ;19: : 588– 593 .
    [Google Scholar]
  100. [100]. Hearn   RM., , Kerr   AC., , Rahim   KF., , Ferguson   J., , Dawe   RS. . Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy. . Br J Dermatol . 2008; ;159: : 931– 935 .
    [Google Scholar]
  101. [101]. Bhatnagar   A., , Kanwar   AJ., , Parsad   D. . Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. . J Eur Acad Dermatol Venereol . 2007; ;21: : 638– 642 .
    [Google Scholar]
  102. [102]. El Mofty   M., , Mostafa   W., , Esmat   S., , Youssef   R., , Azzam   O., , Hunter   N., , El Hanafi   G., , Fawzi   M. . Narrow band UVB 311 nm in the treatment of vitiligo: two right-left comparison studies. . Photodermatol Photoimmunol Photomed . 2001; ;22: : 6– 11 .
    [Google Scholar]
  103. [103]. Mofty   ME., , Zaher   H., , Esmat   S., , Yossef   R., , Shahin   Z., , Bassioni   D., , Enani   GE. . PUVA and PUVB in vitiligo-are they equally effective?.   Photodermatol Photoimmunol Photomed . 2001; ;17: : 159– 163 .
    [Google Scholar]
  104. [104]. US Food and Drug Administration web site. Available from: www.fda.gov .
  105. [105]. Sassi   F., , Cazzaniga   S., , Tessari   G., , Chatenoud   L., , Reseghetti   A., , Marchesi   L., , Girolomoni   G., , Naldi   L. . Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. . Br J Dermatol . 2008; ;159: : 1186– 1191 .
    [Google Scholar]
  106. [106]. Kawalek   AZ., , Spencer   JM., , Phelps   RG. . Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. . Dermatol Surg . 2004; ;30: : 130– 135 .
    [Google Scholar]
  107. [107]. Goldinger   SM., , Dummer   R., , Schmid   P., , Burg   G., , Siefert   B., , Lauchli   S. . Combination of 308-nm xenon excimer laser and topical calcipotriol in vitiligo. . J Eur Acad Dermatol Venereol . 2007; ;21: : 504– 508 .
    [Google Scholar]
  108. [108]. Lu-yan   T., , Wen-wen   F., , Lei-hong   X., , Yi   J., , Zhi-zhong   Z. . Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. . Photodermatol Photoimmunol Photomed . 2006; ;22: : 310– 314 .
    [Google Scholar]
  109. [109]. Lotti   T., , Buggiani   G., , Troiano   M., , Assad   GB., , Delescluse   J., , De Giorgi   V., , Hercogova   J. . Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. . Dermatol Ther . 2008; ;21: suppl 1 : s20– s26 .
    [Google Scholar]
  110. [110]. Wu   CS., , Hu   SC., , Lan   CC., , Chen   GS., , Chuo   WH., , Yu   HS. . Low-energy helium-neon laser therapy induces repigmentation and improves the abnormalities of cutaneous microcirculation in segmental-type vitiligo lesions. . Kaohsiung J Med Sci . 2008; ;24: : 180– 189 .
    [Google Scholar]
  111. [111]. Lan   CC., , Wu   CS., , Chiou   MH., , Hsieh   PC., , Yu   HS. . Low-energy helium-neon laser induces locomotion of immature melanoblasts and promotes melanogenesis of the more differentiated melanoblasts: recapitulation of vitiligo repigmentation in vitro. . J Invest Dermatol . 2006; ;126: : 2119– 2126 .
    [Google Scholar]
  112. [112]. Yu   HS., , Wu   CS., , Yu   CL., , Kao   YH., , Chiou   MH. . Helium-neon laser irradiation stimulates migration and proliferation in melanocytes and induces repigmentation in segmental-type vitiligo. . J Invest Dermatol . 2003; ;120: : 56– 64 .
    [Google Scholar]
  113. [113]. Pasricha   JS., , Seetharam   KA., , Dashore   A. . Evaluation of five different regimes for the treatment of vitiligo. . Indian J Dermatol Venereol Leprol . 1989; ;55: : 18– 21 .
    [Google Scholar]
  114. [114]. Pasricha   JS., , Khaitan   BK. . Oral mini-pulse therapy with betametha- sone in vitiligo patients having extensive or fast-spreading disease. . Int J Dermatol . 1993; ;32: : 753– 757 .
    [Google Scholar]
  115. [115]. Radakovic-Fijan   S., , Furnsinn-Fridl   AM., , Honigsmann   H., , Tanew   A. . Oral dexamethasone pulse treatment for vitiligo. . J Am Acad Dermatol . 2001; ;44: : 814– 817 .
    [Google Scholar]
  116. [116]. Kim   SM., , Lee   HS., , Hann   SK. . The efficacy of low-dose oral corticosteroids in the treatment of vitiligo. . Int J Dermatol . 1999; ;38: : 546– 550 .
    [Google Scholar]
  117. [117]. Rath   N., , Kar   HK., , Sabhnani   S. . An open labeled, comparative clinical study on ef?cacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrow band UVB phototherapy in progressive vitiligo. . Indian J Dermatol Venereol Leprol . 2008; ;74: : 357– 360 .
    [Google Scholar]
  118. [118]. Dell'Anna   ML., , Picardo   M. . A review and new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. . Pigment Cell Res . 2006; ;19: : 406– 411 .
    [Google Scholar]
  119. [119]. Prasad   D., , Pandhi   R., , Juneja   A. . Effectiveness of oral ginkgo biloba in treating limited, slowly spreading vitiligo. . Clin Exp Dermatol . 2003; ;28: : 285– 287 .
    [Google Scholar]
  120. [120]. Dell'Anna   ML., , Mastrofrancesco   A., , Sala   R., , Venturini   M., , Ottaviani   M., , Vidolin   AP., , Leone   G., , Calzavara   PG., , Westerhof   W., , Picardo   M. . Antioxidant and narrow band-UVB in the treatment of vitiligo: a double-blind placebo-controlled trial. . Clin Exp Dermatol . 2007; ;32: : 631– 636 .
    [Google Scholar]
  121. [121]. Middelkamp-Hup   MA., , Bos   JD., , Rius-Diaz   F., , Gonzales   S., , Westerhof   W. . Treatment of vitiligo vulgaris with narrow-band UVB and oral polypodium leucotomos extract: a randomized double-blind placebo-controlled study. . J Eur Acad Dermato Venereol . 2007; ;21: : 942– 950 .
    [Google Scholar]
  122. [122]. Schallreuter   KU., , Wood   JM., , Lemke   KR., , Levenig   C. . Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. . Dermatology . 1995; ;190: : 223– 229 .
    [Google Scholar]
  123. [123]. Schallreuter   KU., , Moore   J., , Behrens-Willams   S., , Panske   A., , Harari   M. . Rapid initiation of repigmentation in vitiligo with dead sea climatotherapy in combination with pseudocatalase (PC-KUS). . Int J Dermatol . 2002; ;41: : 482– 487 .
    [Google Scholar]
  124. [124]. Sanclemente   G., , Garcia   JJ., , Zuleta   JJ., , Diehl   C., , Correa   C., , Falabella   R. . A double-blind, randomized trial of 0.05% betamethasone vs topical catalase/dismutase superoxide in vitiligo. . J Eur Acad Dermato Venereol . 2008; ;22: : 1359– 1364 .
    [Google Scholar]
  125. [125]. Yuskel   EP., , Aydin   F., , Senturk   N., , Canturk   T., , Turanli   AY. . Comparison of the efficacy of narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. . Eur J Dermatol . 2009; ;19: : 341– 344 .
    [Google Scholar]
  126. [126]. Patel   DC., , Evans   AV., , Hawk   JL. . Topical pseudocatalase mousse and narrowband UVB phototherapy is not effective for vitiligo: an open, single-center study. . Clin Exp Dermatol . 2002; ;27: : 641– 644 .
    [Google Scholar]
  127. [127]. Kim   CY., , Yoon   TJ., , Kim   TH. . Epidermal grafting after chemical ablation in the treatment of vitiligo. . Dermatol Sur . 2001; ;27: : 855– 856 .
    [Google Scholar]
  128. [128]. Gupta   S., , Shroff   S., , Gupta   S. . Modified technique of suction blistering for epidermal grafting in vitiligo. . Int J Dermatol . 1999; ;38: 306 : 9 .
    [Google Scholar]
  129. [129]. Acikel   C., , Ulkur   E., , Celikoz   B. . Carbon dioxide laser resurfacing and thin skin graft in the treatment of “stable and recalcitrant” vitiligo. . Plast Reconstr Surg . 2003; ;111: : 1291– 1298 .
    [Google Scholar]
  130. [130]. Agrawal   K., , Agrawal   A. . Vitiligo: repigmentation with dermabrasion and thin split-thickness skin graft. . Dermatol Sur . 1995; ;21: : 295– 300 .
    [Google Scholar]
  131. [131]. Ozdemir   M., , Cetinkale   O., , Wolf   R., , Kotoğyan   A., , Mat   C., , Tüzün   B., , Tüzün   Y. . Comparison of two surigal approaches for treating vitiligo: a preliminary study. . Int J Dermatol . 2002; ;41: : 135– 138 .
    [Google Scholar]
  132. [132]. Lim   JT. . Repigmentation of vitiligo with autologous blister-induced epidermal graft. . Ann Acad Med Singapore . 1992; ;28: : 824– 828 .
    [Google Scholar]
  133. [133]. Awad   SS., , Abdel-Raof   H., , Hosam El-Din   W., , El-Domiaty   M. . Epithelial grafting for vitiligo requires ultraviolet A phototherapy to increase success rate. . J Cosm Dermatol . 2007; ;6: : 119– 124 .
    [Google Scholar]
  134. [134]. Malakar   S., , Dhar   S. . Treatment of stable and recalcitrant vitiligo by autologous miniature punch grafting: a prospective study of 1,000 patients. . Dermatology . 1999; ;198: : 133– 139 .
    [Google Scholar]
  135. [135]. Lahiri   K., , Malakar   S., , Sarma   N., , Banerjee   U. . Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311 nm)—a prospective study. . Int J Dermatol . 2006; ;45: : 649– 655 .
    [Google Scholar]
  136. [136]. Pandya   V., , Parmar   KS., , Shah   BJ., , Bilimoria   FE. . A study of autologous melanocyte transfer in treatment of stable vitiligo. . Indian J Dermatol Venereol Leprol . 2005; ;71: : 393– 397 .
    [Google Scholar]
  137. [137]. van Geel   N., , Ongenae   K., , De Mil   M., , Haeghen   YV., , Vervaet   C., , Naeyaert   JM. . Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repig- menting vitiligo. . Arch Dermatol . 2004; ;140: : 1203– 1208 .
    [Google Scholar]
  138. [138]. Mulekar   SV. . Long-term follow-up study of 142 patients with vitiligo vulgaris treated by autologous, non-cultured melanocyte-keratinocyte cell transplantation. . Int J Dermatol . 2005; ;44: : 841– 845 .
    [Google Scholar]
  139. [139]. Khandpur   S., , Sharma   VK., , Manchanda   Y. . Comparison of minipunch grafting versus split-skin grafting in chronic stable vitiligo. . Dermatol Surg . 2005; ;31: : 436– 441 .
    [Google Scholar]
  140. [140]. Barman   KD., , Khaitan   BK., , Verma   KK. . A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo. . Dermatol Surg . 2004; ;30: : 49– 53 .
    [Google Scholar]
  141. [141]. Lahiri   K., , Malakar   S., , Sarma   N., , Banerjee   U. . Repigmentation of vitiligo with punch grafting and narrow-band UV-B (311 nm)—a prospective study. . Int J Dermatol . 2006; ;45: : 649– 655 .
    [Google Scholar]
  142. [142]. Tanioka   M., , Yamamoto   Y., , Kato   M., , Miyachi   Y. . Camou?age for patients with vitiligo vulgaris improved their quality of life. . J Cos- met Dermatol . 2010; ;9: : 72– 75 .
    [Google Scholar]
  143. [143]. DePase   A. . ‘La Voce dei Pazienti’. Evidence Based Dermatology . Milan: : Masson Publisher;   2003; .
    [Google Scholar]
  144. [144]. Ongenae   K., , Dierckxsens   L., , Brochez   L., , van Geel   N., , Naeyaert   JM. . Quality of life and stig- matization pro?le in a cohort of vitiligo patients and effect of the use of camou?age. . Dermatology . 2005; ;210: : 279– 285 .
    [Google Scholar]
  145. [145]. Savin   J. . The hidden face of dermatology. . Clin Exp Dermatol . 1993; ;18: : 393– 395 .
    [Google Scholar]
  146. [146]. De Cuyper   C. . Permanent makeup: indications and complications. . Clin Dermatol . 2008; ;26: : 30– 34 .
    [Google Scholar]
  147. [147]. Mosher   DB., , Parrish   JA., , Fitzpatrick   TB. . Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. . Br J Dermatol . 1977; ;97: : 669– 679 .
    [Google Scholar]
  148. [148]. Njoo   MD., , Vodegel   RM., , Westerhof   W. . Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q- switched ruby laser. . J Am Acad Dermatol . 2000; ;42: : 760– 769 .
    [Google Scholar]
  149. [149]. Rao   J., , Fitzpatrick   RE. . Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. . Dermatol Surg . 2004; ;30: : 1043– 1045 .
    [Google Scholar]
  150. [150]. Linthorst Homan   MW., , Spuls   PI., , De Korte   J., , Bos   JD., , Sprangers   MA., , van der Veen   JP. . The burden of vitiligo: patient characteristics associated with quality of life. . J Am Acad Dermatol . 2009; ;61: : 411– 420 .
    [Google Scholar]
  151. [151]. Thompson   AR., , Clarke   SA., , Newell   RJ., , Gawkrodger   DJ., , Appearance Research Collaboration. . Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. . Br J Dermatol . 2010; ;163: : 481– 486 .
    [Google Scholar]
  152. [152]. Kostoupolou   P., , Taieb   A. . Psychological interventions. . In: Picardo   M., Taieb   A. , eds. Vitiligo . Berlin: : Springer;   2009; ; : 433– 435 .
    [Google Scholar]
  153. [153]. Kostopolou   P., , Juoary   T., , Quintard   B., , Ezzedine   K., , Marques   S., , Boutchnei   S., , Taieb   A. . Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral center. . Br J Dermatol . 2009; ;161: : 128– 133 .
    [Google Scholar]
  154. [154]. Talsania   N., , Lamb   B., , Bewley   A. . Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. . Clin Exp Dermatol . 2009; ;35: : 736– 739 .
    [Google Scholar]
  155. [155]. Birol   A., , Kisa   U., , Kurtipek   GS., , Kara   F., , Kocak   M., , Erkek   E., , Caglayan   O. . Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. . Int J Dermatol . 2006; ;45: : 992– 994 .
    [Google Scholar]
  156. [156]. Simon   JA., , Burgos-Vargas   R. . Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. . Dermatology . 2008; ;216: : 234– 235 .
    [Google Scholar]
  157. [157]. Wakkee   M., , Assen   YJ., , Thio   HB., , Neumann   HA. . Repigmentation of vitiligo during eflizumab. . J Am Acad Dermatol . 2008; ;59: 2 Suppl 1 : S57– S58 .
    [Google Scholar]
  158. [158]. Al-Mutairi   N., , Al-Doukhi   A. . Familial and colocalized psoriasis and vitiligo responding to alefacept. . J Cutan Med Surg . 2009; ;13: : 172– 175 .
    [Google Scholar]
  159. [159]. Radmanesh   M., , Saedi   K. . The Efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. . J Dermatol Treat . 2006; ;17: : 151– 153 .
    [Google Scholar]
  160. [160]. Dogra   S., , Kumar   B. . Repigmentation in vitiligo universalis: role of melanocyte density, disease duration, and melanocytic reservoir. . Dermatol Online J . 2005; ;11: 3 : 30 .
    [Google Scholar]
  161. [161]. Pardue   SL., , Fite   KV., , Bengston   L., , Lamont   SJ., , Boyle   ML 3rd., , Smyth   JR Jr. . Enhanced integumental and ocular amelanosis following the termination of cyclosporine administration. . J Invest Dermatol . 1987; ;88: : 758– 761 .
    [Google Scholar]
  162. [162]. Mahmoud   CL., , Hexel   IH. . Update on new and emerging options for the treatment of vitiligo. . Skin Ther Letter . 2008; ;13: 2 : 1– 6 .
    [Google Scholar]
  163. [163]. Sethi   RR., , Mahajan   A. . evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical Placentrex® gel in localized stable vitiligo. . Int J Dermatol . 2007; ;46: 8 : 875– 879 .
    [Google Scholar]
  164. [164]. Whitton   J., , Pinart   U., , Batchelor   J., , Lushey   C., , Leonardi-Bee   J., , González   U. . for vitiligo. . Cochrane Database Syst Rev . 2010; ;20: : 1– 142 .
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2013.10
Loading
/content/journals/10.5339/qmj.2013.10
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error